Table 3
Individual statins: recorded exposure and association with AMD
| Variable | Cases (n = 18007) | Controls (n = 86169) | Adjusted odds ratio* (95% CI) | p Value |
|---|---|---|---|---|
| *Adjusted for all potential confounders significantly associated with both AMD and statin use (that is, consultation rate (quintiles), smoking, alcohol intake, BMI, atherosclerosis, hyperlipidaemia, heart failure, diabetes, hypertension, cardiovascular drug use (excluding aspirin or statin), fibrate use). People with missing data are included as separate strata. | ||||
| †People who received a prescription for more than one type of statin. | ||||
| No statin | 17632 (97.9%) | 84751 (98.4%) | Baseline | |
| Any statin exposure | 375 (2.1%) | 1418 (1.6%) | 0.93 (0.81–1.07) | 0.33 |
| Atorvastatin only | 29 (0.16%) | 138 (0.16%) | 0.76 (0.50–1.15) | 0.19 |
| Cerivastatin only | 10 (0.06%) | 53 (0.06%) | 0.65 (0.33–1.28) | 0.21 |
| Fluvastatin only | 11 (0.06%) | 35 (0.04%) | 1.10 (0.54–2.21) | 0.80 |
| Pravastatin only | 47 (0.26%) | 165 (0.19%) | 0.99 (0.70–1.39) | 0.95 |
| Simvastatin only | 226 (1.26%) | 836 (0.97%) | 0.97 (0.82–1.15) | 0.70 |
| Mixed† | 52 (0.29%) | 191 (0.22%) | 0.91 (0.65–1.26) | 0.57 |
